Phase III chemotherapy trials in small cell lung cancer

A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer.

1989 • 467 citations

Doxorubicin-containing regimens for the treatment of stage II breast cancer: The National Surgical Adjuvant Breast and Bowel Project experience.

1989 • 152 citations

Cisplatin plus etoposide consolidation following cyclophosphamide, doxorubicin, and vincristine in limited small-cell lung cancer.

1988 • 125 citations

Cisplatin/etoposide versus ifosfamide/etoposide combination chemotherapy in small-cell lung cancer: a multicenter German randomized trial.

1987 • 87 citations

Teniposide (VM-26), an overlooked highly active agent in small-cell lung cancer. Results of a phase II trial in untreated patients.

1986 • 73 citations

Etoposide combined with cyclophosphamide plus vincristine compared with doxorubicin plus cyclophosphamide plus vincristine and with high-dose cyclophosphamide plus vincristine in the treatment of small-cell carcinoma of the lung: a randomized trial of the Bristol Lung Cancer Study Group.

1989 • 55 citations

The superiority of combination chemotherapy including etoposide based on in vivo cell cycle analysis in the treatment of extensive small-cell lung cancer: a randomized trial of 288 consecutive patients.

1987 • 50 citations

Treatment of small-cell carcinoma of the lung monitored by sequential flow cytometric DNA analysis.

1982 • 40 citations

Improvement of long-term survival in extensive small-cell lung cancer.

1988 • 39 citations

Extensive stage small cell carcinoma of the bronchus

1987 • 20 citations

Small-cell lung cancer: a 10-year perspective.

1986 • 18 citations

A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer

1990 • 12 citations